JewishStatusOpen the app

Tachlis Daily Status · Nov 12, 2026

Tachlis Daily Status — photo status

👁️ Sandoz Launches Lupin's Biosimilar Eye Treatment Across Europe, Excluding Germany Sandoz has launched Ranluspec, a ranibizumab biosimilar developed by Lupin, across Europe excluding Germany. The rollout follows European Commission approval for retinal diseases and is not a new U.S. approval. Read more: ✨ #1 Source for Tachlis! News. Media. Music. Simchas. 🫵 JOIN OUR STATUS:

👁️ *Sandoz Launches Lupin's Biosimilar Eye Treatment Across Europe, Excluding Germany* Sandoz has launched Ranluspec, a ranibizumab biosimilar developed by Lupin, across Europe excluding Germany. The rollout follows European Commission approval for retinal diseases and is not a new U.S. approval. *Read more:* https://tachlisdaily.com/news/sandoz-launches-lupin-s-biosimilar-eye-treatment-across-europe-excluding-germany ✨ *_#1 Source for Tachlis! News. Media. Music. Simchas._* 🫵 *JOIN OUR STATUS: https://wa.me/17328067662?text=%20SubscribeViaSM%20*

Watch in the app All of Tachlis Daily Status's statuses

More from Tachlis Daily Status